Core Viewpoint - The global GLP-1 market is shifting, with multinational pharmaceutical companies increasingly focusing on Chinese biopharmaceutical assets, a trend expected to peak in 2025 and be confirmed in early 2026 [5] Group 1: Market Dynamics - The competition in the weight loss and metabolic disease market is evolving from single product competition to a comprehensive contest involving multiple mechanisms, indications, and long-term medication [5] - Multinational pharmaceutical companies are experiencing anxiety regarding pipeline breadth and technological reserves, with China emerging as a key source for supplementing GLP-1 pipelines [5] - Over the past decade, the role of Chinese innovative drug companies has shifted from introducing overseas technology to exporting self-developed assets [5] Group 2: Asset Development - Chinese companies have accumulated a number of candidates in the GLP-1 field, particularly in dual-target, triple-target, and oral formulations, with several in Phase II and III [5] - These assets are characterized by preliminary validation of scientific pathways and identifiable clinical risks, making them valuable for multinational companies to quickly fill their pipelines through licensing or acquisition [5] Group 3: Transaction Highlights - Novo Nordisk made a significant move by securing rights to a triple-target agonist, UBT251, with a payment structure of $200 million upfront and up to $1.8 billion in milestone payments, reflecting a strategic choice to rebuild its next-generation weight loss product lineup [7] - Regeneron entered a licensing agreement with Hansoh Pharma worth over $2 billion for a GLP-1/GIP dual-target agonist in Phase III, aiming to strengthen its position in the metabolic disease field [7] - Pfizer, after terminating two late-stage oral GLP-1 candidates due to safety issues, acquired Metsera for nearly $10 billion and entered a licensing agreement with YaoPharma for an early-stage oral GLP-1 candidate, demonstrating a cautious approach to re-entering the oral weight loss drug market [7] Group 4: Strategic Implications - These transactions signal that multinational pharmaceutical companies are preparing for the second phase of competition in the GLP-1 market, focusing on efficacy limits, medication convenience, long-term safety, and combination therapy potential [8] - The shift indicates a structural adjustment in the global pharmaceutical industry, with China transitioning from merely a clinical trial and production base to a significant technology supplier in key therapeutic areas [8]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The report highlights the strong performance of WuXi AppTec and its subsidiaries, indicating robust growth momentum in the CXO sector. WuXi AppTec is expected to achieve a revenue of CNY 45.456 billion in 2025, representing a year-on-year increase of 15.84%, with TIDES business revenue projected to grow over 90% [2][21]. - The report emphasizes the recovery and structural upgrade trends in the CXO industry, driven by the resurgence of demand and the warming of investment in the innovative drug supply chain [23]. Summary by Sections Market Review - Last week, the pharmaceutical and biotechnology index fell by 0.39%, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 1.50 percentage points, ranking 27th among 31 sub-industries [1][16]. Company Performance - WuXi AppTec's subsidiaries reported strong earnings forecasts, with WuXi Biologics adding 209 comprehensive projects in 2025, two-thirds of which are bispecific antibodies and ADC drugs. The company aims for a compound annual growth rate of 30%-35% in revenue from 2025 to 2030 [2][22]. - The report recommends focusing on CXO chain companies such as WuXi AppTec (A+H), WuXi Biologics (H), and WuXi AppTec's subsidiaries, indicating a positive outlook for these firms [23][27]. Investment Strategy - The report suggests that future investments in the pharmaceutical sector should increasingly focus on the clinical value of drugs, driven by domestic and international policy changes. It highlights the importance of innovative drug supply chains and high-end medical devices, recommending companies like Mindray Medical and United Imaging Healthcare [3][25]. Financial Projections - Key companies are projected to show significant growth, with earnings per share (EPS) and price-to-earnings (PE) ratios indicating strong investment potential. For instance, WuXi AppTec is expected to have an EPS of CNY 5.07 in 2025, with a PE ratio of 19 [4]. Clinical Development Updates - Recent clinical developments include new applications for drugs from companies like InnoCare Pharma and Hengrui Medicine, with several drugs in various clinical trial phases [31][32]. Market Dynamics - The report notes that the pharmaceutical manufacturing industry experienced a year-on-year revenue decline of 2.0% in the first eleven months of 2025, indicating challenges in the sector [52]. Policy and Economic Environment - The report discusses the structural shift in domestic policies favoring innovative drugs and the anticipated global demand growth due to aging populations, which is expected to benefit the pharmaceutical industry [26].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [5][7]. Core Viewpoints - Continuous support policies are being implemented, which are expected to benefit innovative surgical projects and retail pharmacy chains [2][5]. - The report highlights the high growth potential in innovative pharmaceuticals, recommending companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical for overweight ratings [5][7]. - The report also emphasizes the recovery of the CXO and upstream pharmaceutical sectors, recommending companies like WuXi AppTec, WuXi Biologics, and others for overweight ratings [5][7]. Summary by Sections Innovative Pharmaceuticals and Medical Devices - The report continues to recommend the innovative pharmaceutical sector, indicating a potential revaluation of companies like Heng Rui Medicine and others [5][7]. - It highlights the gradual realization of innovative pipelines and the performance growth of Biopharma/Biotech companies, maintaining overweight ratings for several key players [5][7]. Market Performance - In the fourth week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the SW pharmaceutical and biological index declining by 0.4% compared to a 0.8% increase in the Shanghai Composite Index [9][14]. - The report notes that the pharmaceutical sector's premium level relative to the entire A-share market is currently at a normal level, with a relative premium rate of 65.4% as of January 23, 2026 [14][18]. Stock Recommendations - The report provides a detailed earnings forecast and valuation for various companies, maintaining overweight ratings for multiple firms across different segments, including innovative pharmaceuticals, medical devices, and consumer healthcare [8][5].

Market Overview - The pharmaceutical sector is experiencing a structural bull market in 2025, with the CITIC Pharmaceutical Index rising nearly 30% in the first three quarters, driven by the global recognition of the value of innovative drugs and devices [2][3] - The industry is expected to enter a critical phase of innovation realization and global expansion in 2026, shifting investment logic from expectation-driven to closely tracking clinical data, commercialization progress, and international achievements [2][3] Valuation Insights - The pharmaceutical sector's valuation remains at historical lows, with significant investment opportunities still available. As of December 31, 2025, various sub-sectors are trading at relatively low valuations, such as biopharmaceuticals at 35.16X and medical devices at 33.07X [7][9] - The medical services, chemical raw materials, and chemical preparations sectors have shown impressive growth, with increases of 29.22%, 22.03%, and 20.44% respectively [7] Revenue and Profit Trends - From January to November 2025, China's pharmaceutical manufacturing industry reported total revenue of 220.65 billion yuan, a year-on-year decline of 2.51%, while total profit decreased by 1.79% [9] - The performance of the biopharmaceutical, medical services, and pharmaceutical distribution sectors has improved, with biopharmaceuticals benefiting from rapid drug volume growth post-collection [9] Fund Management and Investment Opportunities - As of the end of Q3 2025, public funds' holdings in the pharmaceutical sector were at 11.22%, below the ten-year average of 8.15%, indicating potential for excess returns as the sector approaches a performance inflection point [11] - The low allocation of public funds and the sector's historical low valuations present significant opportunities for investment in high-potential sub-sectors and individual stocks [11] Innovation and Policy Support - The Chinese biopharmaceutical industry is entering a new phase of high-quality development, with significant improvements in innovation capabilities among the top 100 pharmaceutical companies [14][21] - The government has implemented comprehensive policies to support the development of innovative drugs and medical devices, transitioning from single-item support to a full-chain, regional, and financial support system [15][28] Global Market Position - China has become the second-largest market for innovative drug launches globally, contributing approximately 30% of the world's innovative pipelines as of Q3 2025 [50][66] - The country is increasingly recognized for its efficiency and cost-effectiveness in drug development, with a significant number of clinical trials initiated in China, particularly in oncology [53][66] Licensing and Commercialization Trends - The number of license-out transactions for Chinese innovative drugs has surged, with 103 deals recorded in the first three quarters of 2025, totaling $92.03 billion, marking a 77% increase year-on-year [43][63] - The successful inclusion of innovative drugs in the new commercial insurance directory is expected to enhance their commercialization prospects [30] Future Growth Areas - Next-generation therapies, including ADCs, bispecific antibodies, and cell and gene therapies, are becoming focal points for research and investment, with China leading in these areas [76][87] - The oncology drug market is projected to reach $441 billion, with new therapies expected to account for about 20% of treatment expenditures by 2029 [82]

Group 1 - The economic operation characteristic of "production stronger than demand, external demand better than internal demand" has persisted throughout the year, with macroeconomic indicators showing weakness and a loose monetary policy environment [2][3][6] - Industrial production remains resilient, with December's industrial added value growing by 5.2% year-on-year, exceeding expectations [6][36] - The export amount in December increased by 6.6% year-on-year, also better than expected [6][36] Group 2 - Recent weeks have seen a significant outflow of funds from broad-based ETFs, exceeding 570 billion yuan, while thematic industry ETFs have seen inflows of around 110 billion yuan [3][12][43] - The current market sentiment remains high, with investor sentiment indices indicating a state of excitement, suggesting potential short-term risks [10][40] Group 3 - The focus on investment should be on "technology + resource products," with AI semiconductors and new energy being the core areas of current prosperity [4][35] - Emerging hotspots such as AI applications, space photovoltaics, and innovative pharmaceuticals are continuously catalyzing market interest [4][50][51] Group 4 - The non-ferrous metals industry has the highest forecasted performance rate for 2025, indicating a positive outlook for the sector [5][54] - The South China Metal Index has risen by 12.5% since December, while energy and industrial product indices have only increased by about 7%, suggesting better investment value in the non-ferrous sector [5][54] Group 5 - The AI and semiconductor sectors maintain high levels of prosperity, driven by demand for AI model training and inference, which boosts the associated supply chain [50] - The lithium battery sector is experiencing a recovery, supported by growth in new energy vehicles and energy storage [50][51]

Investment Rating - The report suggests a positive outlook for the innovative drug sector, indicating it will continue to be a core investment direction in 2026 due to the maturation of the industry chain and normalization of medical insurance negotiations [4]. Core Insights - The public fund's pharmaceutical holdings decreased to 8.11% in Q4 2025, down by 1.66 percentage points (pp) from the previous quarter. Excluding actively managed pharmaceutical funds, the holdings dropped to 3.90%, a decrease of 1.36pp [11][12]. - The innovative drug ETF reached a scale of 100.62 billion yuan in Q4, accounting for 13.11% of the pharmaceutical fund, which is a slight decrease of 1.35pp [13][15]. - The CXO sector saw a decline in holdings due to geopolitical disturbances, while the medical device sector benefited from innovations like brain-computer interfaces and surgical robots, leading to an increase in holdings [14][17]. - The report highlights the acquisition of PART by GSK for $2.2 billion to strengthen its position in the IgE antibody market, with the core product Ozureprubart showing significant market potential [2][31]. - The oral weight loss drug Wegovy has shown strong early commercial progress, with retail prescriptions reaching approximately 3,071 in the first four days post-launch, nearly three times that of its competitor Zepbound [2][31]. Summary by Sections Pharmaceutical Sector - The report indicates a significant decrease in public fund holdings in the pharmaceutical sector, with a noted resilience in the innovative drug segment [11][14]. - The report emphasizes the importance of focusing on leading companies with core pipeline competitiveness and global layout capabilities for investment [4]. Medical Devices - The introduction of new pricing guidelines for auxiliary medical services is expected to accelerate the adoption of innovative products in the medical device sector [3][17]. - The report suggests monitoring domestic leading companies in this sector for increasing product penetration [3]. Drugstores - The report discusses the potential for leading drugstore companies to increase market share, supported by recent government policies promoting high-quality development in the retail pharmaceutical industry [3][17]. - Specific companies like Yifeng Pharmacy and Dazhenglin are highlighted as having low valuations and significant cost reduction achievements [3]. CXO and Pharmaceutical Supply Chain - Several CXO companies have released optimistic earnings forecasts for 2025, indicating a clear upward trend in industry prosperity [2][31]. - The report recommends active investment in this sector due to the positive signals regarding industry growth [2][31].

Core Insights - The article highlights that Jiangsu Province led the nation in IPOs in 2025, with 46 companies listed, accounting for 15% of the national total [5][6][11] - The report emphasizes the long-term development of Jiangsu's capital efficiency and industrial ecosystem, which has resulted in a significant increase in IPO activity [6][19] Summary by Sections IPO Data Overview - In 2025, a total of 294 IPOs occurred nationwide, with Jiangsu Province achieving the highest number [5] - The total IPO amount for Jiangsu reached 40.858 billion yuan, more than doubling from the previous year [6] Industry Distribution - The majority of IPOs in Jiangsu were concentrated in advanced manufacturing, healthcare, and energy/mining, which together accounted for 71.8% of the total [8] - Notable companies include Jiangsu's largest IPO, United Power, valued at approximately 66 billion yuan, and Qiangyi Co., valued at 48 billion yuan [10] Regional Insights - Suzhou emerged as the leading city in Jiangsu with 19 IPOs, representing 41.3% of the province's total [11] - Jiangsu's IPOs were distributed across 11 cities, with significant contributions from cities like Wuxi and Changzhou [11][13] Long-term Trends - Over the past five years, Jiangsu has facilitated the listing of 265 companies, establishing itself as a key player in the capital market [18][21] - The province's investment events have increased significantly, from 272 in 2013 to nearly 2000 in recent years, indicating a robust investment environment [20] Role of Venture Capital - A high percentage of IPO companies in Jiangsu (87%) had received VC/PE investment, surpassing the national average of 57.8% [19] - Local investment institutions have been active, with five of the top ten direct investment institutions in China based in Jiangsu [25] Future Outlook - Jiangsu has launched several large-scale investment funds, including a 50 billion yuan mother fund, which is expected to sustain investment activity in the coming years [26] - The province's entrepreneurial landscape is characterized by a high number of engineers as founders, focusing on practical industrial opportunities [34][36]

在这一年的交易热潮中，跨国巨头们的采购风格各有不同。谁出手频次最高？谁手笔最大？经济观 察报分析了全年150多笔交易，复盘跨国药企的投资画像与交易特色。 多位受访者对经济观察报表示，其所在药企与潜在合作方达成了进一步沟通意向，他们判断2026 年中国创新药对外授权交易热仍会持续。 2025年爆发式增长的对外授权交易验证了中国创新药资产的价值，该年对外授权总交易额超1300 亿美元，交易数超150笔（约占全球40%），创下历史新高。 阿斯利康最活跃 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共出手了5次。 合作方包括石药集团（01093.HK）、和铂医药（02142.HK）、加科思药业（01167.HK）、元 思生肽等。其中，在2025年6月与石药集团达成的潜在总交易额超53亿美元的合作，可排进年度 交易额前四。在资产选择上，阿斯利康主要集中在临床早期管线，以及技术平台合作。 在交易频次上，阿斯利康是最活跃的跨国药企，2025年一共 出手了5次。从立即兑现的首付款看，辉瑞与武田制药出手最 阔绰。 作者：张英 封图：图虫创意 作为中国市场销售额最高的外资药企，在经历2024年的公司治理风暴后，阿斯利康 ...

Core Insights - The 2026 JPMorgan Healthcare Conference highlighted significant interest from multinational companies in Chinese assets, particularly in the innovative drug sector [1][2] Group 1: Market Trends - The trend of foreign licensing deals for Chinese innovative drugs is expected to continue in 2026, following a record-breaking year in 2025 where the total licensing deal value exceeded $130 billion, accounting for approximately 40% of global transactions [3] - The surge in licensing deals in 2025 validated the value of Chinese innovative drug assets, with over 150 transactions recorded [3] Group 2: Key Players - AstraZeneca emerged as the most active multinational company in 2025, engaging in five transactions, including a notable deal with CSPC Pharmaceutical Group valued at over $5.3 billion [4] - Pfizer and Eli Lilly each conducted four transactions, with Pfizer's deal with 3SBio setting a record for upfront payments in Chinese innovative drugs at $1.25 billion [5] - GSK's collaboration with Heng Rui Medicine reached a potential total of $12.5 billion, marking the highest deal value for Chinese innovative drugs [13] Group 3: Emerging Markets - Interest in Chinese innovative drugs is not limited to Western companies; firms from India, Latin America, and the Middle East are also engaging in licensing deals [7] - Indian companies Glenmark and Dr. Reddy's each completed two business development transactions in 2025, with Glenmark's deals totaling over $2 billion [8][9] Group 4: Financial Highlights - Three companies, AstraZeneca, GSK, and Takeda, signed contracts exceeding $10 billion, while Pfizer and Novartis secured contracts over $5 billion [10] - The largest single transaction was GSK's deal with Heng Rui Medicine, which included rights to one core drug and options for 11 additional projects [13] Group 5: Future Outlook - Executives at the 2026 JPM conference expressed that Chinese assets are an effective way to supplement pipelines, indicating a shift towards acquiring entire biotechnology platforms rather than just single products [14]

本文字数：3320，阅读时长大约5分钟 作者 |第一财经 彭海斌 2026年，中国新药出海热度不减。 1月尚未结束，中国药企已经完成10笔海外授权交易，其中荣昌生物和艾伯维的交易首付款达到6.5亿美 元。 2025年是中国创新药海外交易的大年。第一财经采访的医药和投资机构人士均认为，这种趋势会延续下 去。摩根大通大中华区医疗健康行业研究主管黄旸表示："2026年出海交易数量或者总金额可能难以超 过2025年，但会维持强劲的势头。" 首付款超过一级市场融资 2025年1月，先为达与英国企业Verdiva Bio Limited达成合作。 先为达是一家开发糖尿病及减重药物的中国企业。它将正在临床阶段的口服伊诺格鲁肽等授予后者大中 华区和韩国以外的开发权利。这笔交易的首付款约7000万美元，且可获得最高达24亿美元的潜在开发、 注册和商业化里程碑付款，以及产品商业化后的销售额提成。 2026.01.24 中国代谢领域的交易，是2025年创新药海外授权爆发性增长的缩影。 据医药魔方统计，2025年中国新药对外授权交易158笔，总交易金额1357亿美元，交易数量和金额都达 到十年新高。 事实上，2023年和2024年， ...